Brief: MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
21/05/2024 13:32
May 21 (Reuters) - Mangoceuticals Inc MGRX.O :
* MANGORX TO INTRODUCE ORAL SEMAGLUTIDE AND TIRZEPATIDE IN
RESPONSE TO INCREASING PATIENT DEMAND FOR GLP-1 MEDICATIONS
* MANGOCEUTICALS:TO HAVE PRODUCTS AVAILABLE ON TELEMEDICINE
PLATFORM IN START OF Q3 WITH 'SLIM' AND 'TRIM' PRICED AT
$299/MNTH & $399/MNTH, RESPECTIVELY
Source text for Eikon: ID:nGNX4zDb7z
Further company coverage: MGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mangoceuticals
See all newsBrief: Mangoceuticals And Nuclea Energy Terminate Business Combination Agreement On August 19
Brief: Mangoceuticals Inc.’S Merger Partner, Nuclea Energy, Inc., Enters Into Definitive Agreement To Acquire Moltex Energy’S Advanced Nuclear Technology Assets
NASDAQ RESUMED AT 10:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM
NASDAQ RESUMED AT 10:27 AM